Business
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel discoveries related to requirements for efficient and selective Wnt pathway signaling SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt
About this update from Surrozen, Inc.
[{"type":"image","alt":"Surrozen, Inc.","displaySize":"","headline":null,"caption":"Surrozen, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x6DV722PrEWTqtVALzIaoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_Nw2ZiUnSxKs.uMojTysxg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://ml.globenewswire.com/Resource/Download/1402e192-4e1a-498f-b1b0-f8858e4d4858?size=2","width":1200,"height":675}},"lazy":false},{"type":"text","content":"Newly granted patent is part of the expanding intellectual property portfolio directed to:","length":90,"tagName":"p"},{"type":"text","content":"-generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and","length":102,"tagName":"p"},{"type":"text","content":"-incorporating novel discoveries related to requirements for efficient and selective Wnt pathway signaling","length":106,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced the issuance of U.S. Patent No. 12,297,278.","length":303,"tagName":"p"},{"type":"text","content":"Surrozen has six issued U.S. patents, 10 patents issued in other countries, 11 patent families pending in the U.S. and other countries, five patent families pending in the U.S. only, two pending PCT applications, and four patent families with pending U.S. provisional applications, and has two in-licensed patent families related to the Wnt pathway and its modulation. In May 2025, Surrozen was granted U.S. Patent No. 12,297,278 related to its SWAPTM technology. The patent covers tetravalent, multi-specific Wnt surrogates comprised of: two Frizzled (Fzd) binding regions that specifically bind to two Fzd receptors, wherein each of the two Fzd binding regions comprises an antibody or antigen-binding fragment of the antibody; and two LRP5/6 bind...